#Hyaluronidase vs vtrace trial#

Is also being studied in the treatment of other types ofĬancer. For more information about daratumumab that may apply to daratumumab and hyaluronidase-fihj, see the Drug Information Summary for Daratumumab. This form can be given in less time than daratumumab, which is given as an infusion. As a condition of approval, confirmatory trial(s) must show that daratumumab and hyaluronidase-fihj provides a clinical benefit in these patients.ĭaratumumab and hyaluronidase-fihj is a form of daratumumab that is given as a subcutaneous injection. ¹This use is approved under FDA’s Accelerated Approval Program.

With carfilzomib and dexamethasone in patients who have received one to three types of therapy.

With pomalidomide and dexamethasone in patients who have received at least one therapy that included lenalidomide and a proteasome inhibitor.Alone in patients who have already received at least three types of therapy that included a proteasome inhibitor and an immunomodulating agent or whose disease is refractory to both a proteasome inhibitor and an immunomodulatory agent.With dexamethasone and either lenalidomide or bortezomib in patients who have received at least one therapy.With bortezomib, thalidomide, and dexamethasone in patients who can receive an autologous stem cell transplant.With bortezomib, melphalan, and prednisone or with lenalidomide and dexamethasone in patients who cannot receive an autologous stem cell transplant.It is used with bortezomib,Ĭyclophosphamide, and dexamethasone in adults.¹ Light-chain amyloidosis that is newly diagnosed.Is approved to be used alone or with other drugs to treat: A 10-year experience with 150 cases.FDA label information for this drug is available at DailyMed. Clinical evaluation of different treatment methods for oral submucous fibrosis.

#Hyaluronidase vs vtrace trial#

A randomized double-blind, multiple-arm trial comparing the efficacy of submucosal injections of hyaluronidase, dexamethasone, and combination of dexamethasone and hyaluronidase in the management of oral submucous fibrosis.Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis - a clinical study.A comparative study of various modalities in the treatment of keloids.Betamethasone oral mini-pulse therapy compared with topical triamcinolone acetonide (0.1%) paste in oral lichen planus: A randomized comparative study.Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis.Pentoxifylline therapy in the management of oral submucous fibrosis.Isolated corymbose collagenoma responding to intralesional triamcinolone acetonide and hyaluronidase injections.Comparison of Efficacy of Topical Curcumin Gel with Triamcinolone-hyaluronidase Gel Individually and in Combination in the Treatment of Oral Submucous Fibrosis.Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus.A follow up study is required to see long term effects. INTERPRETATION & CONCLUSION: Treatment regimen of group B was more convenient to the patients because less number of visits required and cheap. RESULTS: No statistically significant difference in symptom score, sign score and histopathological improvement was seen between the two groups.

Student's 't' test was applied for comparing the results. Treatment outcome was evaluated on the basis of improvement in symptom score, sign score and histopathological improvement. Group B patients received combination of triamcinolone acetonide (10 mg/ml)/ hyaluronidase (1500 IU) at 15 days interval for 22 wk. Group A patients received combination of hydrocortisone acetate (1.5 ml)/hyaluronidase (1500 IU) at weekly interval submucosally in pterygomandibular raphe, half dose on each side for 22 wk. METHODS: Patients of OSMF (100) were randomly divided into two groups A and B. In this study we compared the efficacy of hydrocortisone acetate and hyaluronidase at weekly interval versus triamcinolone acetonide and hyaluronidase at 15 days interval. The problem with the prevailing treatment was injections at weekly interval. Its medical treatment is not yet fully standardized, although the optimal doses of its medical treatment is in the form of hydrocortisone acetate combined with hyaluronidase. N2 - BACKGROUND & OBJECTIVES: Oral submucous fibrosis is a common premalignant condition caused by chewing arecanut and other irritants in various forms. JF - The Indian journal of medical research T1 - Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis.